Abstract
AbstractThe unfolded protein response (UPR) is a cellular mechanism that protects cells during stress conditions in which there is an accumulation of misfolded proteins in the endoplasmic reticulum (ER). UPR activates three signaling pathways that function to alleviate stress conditions and promote cellular homeostasis and cell survival. During unmitigated stress conditions, however, UPR activation signaling changes to promote cell death through apoptosis. Interestingly, cancer cells take advantage of this pathway to facilitate survival and avoid apoptosis even during prolonged cell stress conditions. Here, we discuss different signaling pathways associated with UPR and focus specifically on one of the ER signaling pathways activated during UPR, inositol-requiring enzyme 1α (IRE1). The rationale is that the IRE1 pathway is associated with cell fate decisions and recognized as a promising target for cancer therapeutics. Here we discuss IRE1 inhibitors and how they might prove to be an effective cancer therapeutic.
Graphical abstract
Subject
Cell Biology,Molecular Biology,Biochemistry
Reference217 articles.
1. Allagnat F, Christulia F, Ortis F, Pirot P, Lortz S, Lenzen S et al (2010) Sustained production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction and apoptosis. Diabetologia 53(6):1120–1130
2. Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B et al (2019) Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications. Febs J 286(2):241–278
3. Alrasheed M, Alsuhibani A, Hincapie AL, Guo JF (2021) Safety evaluation of panobinostat, ixazomib, elotuzumab, and daratumumab using FDA adverse event reporting system (FAERS) database 2015–2020. Pharmacoepidem Dr S 30:333
4. Alves-Fernandes DK, Oliveira EA, Faiao-Flores F, Alicea-Rebecca G, Weeraratna AT, Smalley KSM et al (2019) ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC). Pharmacol Res 141:63–72
5. Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K et al (2013) Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 73(6):1993–2002
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献